LSE - Delayed Quote GBp
Nuformix plc (NFX.L)
0.1250
0.0000
(0.00%)
At close: May 16 at 4:02:44 PM GMT+1
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Daniel John Gooding | Executive Director | 30k | -- | 1973 |
| Dr. Joanne M. Holland | Consultant | -- | -- | 1975 |
| Shaun Zulafqar | Company Secretary | -- | -- | -- |
Nuformix plc
60 Gracechurch Street
6th Floor
London, EC3V 0HR
United Kingdom
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Corporate Governance
Nuformix plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 2, 2025 at 6:00 AM UTC
Nuformix plc Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
PYC.L Physiomics Plc
0.4200
-1.18%
FAB.L Fusion Antibodies plc
6.75
+7.14%
HPHA.DE Heidelberg Pharma AG
3.2300
+0.94%
VAL.L ValiRx plc
0.5250
0.00%
HEMO.L Hemogenyx Pharmaceuticals Plc
177.50
-0.28%
BIOS.BR BioSenic S.A.
0.0015
-11.76%
OMGAQ
0.0400
+29.03%
AAPG Ascentage Pharma Group Internat
22.65
+0.13%
ENGN enGene Holdings Inc.
3.4500
+1.47%
KLRS Kalaris Therapeutics, Inc.
3.4800
-1.69%